Diabetes mellitus type 2 (for glycemic control with monotherapy failure sulfonylureas or thiazolidinediones, as well as patients who have already received a combined therapy with thiazolidinediones and sulfonylureas). AVANDARYL (Glimepiride, Rosiglitazone) can be used in combination with metformin (triple combination) for glycemic controls.
Dosage and administration
Dosing regimen AVANDARYL (Glimepiride, Rosiglitazone) is selected and set individually. Must take into account the current glycemic control to individual patient and the risk of hypoglycemia. AVANDARYL (Glimepiride, Rosiglitazone) should be taken 1 time / day with meals.
Contraindications
Heart failure (I-IV functional class classification NYHA); acute coronary syndrome (unstable angina, myocardial infarction without ST elevation ST, MI segment elevation ST); renal failure, severe (creatinine clearance less than 30 ml / min), including patients hemodialysis, liver problems, diabetes mellitus type 1, diabetic ketoacidosis or diabetic precoma, galactose intolerance, lactase deficiency or malabsorption of glucose-galactose, age 18 years (there are currently no data on the use AVANDARYL (Glimepiride, Rosiglitazone) in children 18, therefore, the use AVANDARYL (Glimepiride, Rosiglitazone) in this age group is not recommended), the combined use of the insulin-sensitivity to rosiglitazone, glimepiride, other sulfonylureas or sulfonamides or any other component of the drug, galactose intolerance, lactase deficiency, disorders absorption of glucose-galactose.
Side effects
Rosiglitazone.So by blood: anemia, leukopenia, thrombocytopenia, granulocytopenia. On the part of metabolism: hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, weight gain, increased appetite, hypoglycemia. Nervous system disorders: dizziness, headache. Cardio-vascular diseases: heart failure, myocardial ischemia. From the digestive system: constipation. On the part of the musculoskeletal system: broken bones, myalgia. From the body as a whole: edema. Glimepiride. Hematopoietic system: thrombocytopenia, leukopenia, hemolytic anemia, eritropeniya, granulocytopenia, agranulocytosis, pancytopenia. From a metabolism: hypoglycemia, hyponatremia. Eye disorders: blurred vision. From the digestive system: nausea, elevated liver enzymes, gastrointestinal upset (vomiting, a feeling of pressure and overcrowding in the epigastric, abdominal pain and diarrhea), abnormal liver function, manifested cholestasis, jaundice, hepatitis or liver failure.
Overdose
Symptoms: Overdose sulfonylureas, including Glimepiride, can cause severe life-threatening hypoglycemia. Treatment: In case of overdose, it is recommended to carry out proper maintenance therapy, guided by the clinical condition of the patient.
Pharmacological group
Combined oral antidiabetics
Composition
Glimepiride, Rosiglitazone
Cautions
There is currently no data on the use AVANDARYL (Glimepiride, Rosiglitazone) in children up to 18 years, so the use AVANDARYL (Glimepiride, Rosiglitazone) in this age group is not recommended. The initial and maintenance dose AVANDARYL (Glimepiride, Rosiglitazone) in elderly patients should be adequately adjusted due to the possible reduction of renal function in this patient group. Any dose adjustment should be based on evidence of renal function, which should be continuously monitored. In patients with renal insufficiency mild to moderate severity (CC 30-80 ml / min) at the transition from therapy to other sulfonylurea therapy AVANDARYL (Glimepiride, Rosiglitazone) have an increased risk of hypoglycemia, so in such cases, appropriate surveillance. Patients with severe renal impairment (creatinine clearance less than 30 ml / min) AVANDARYL (Glimepiride, Rosiglitazone) is contraindicated. Data on the use of glimepiride in patients undergoing hemodialysis, no. Since adequate data on the use of glimepiride in patients with impaired liver function no, AVANDARYL (Glimepiride, Rosiglitazone) is not recommended in these patients. Women premenopauznogo age with lack of ovulation. Due to the ability of rosiglitazone to increase insulin sensitivity, treatment AVANDARYL (Glimepiride, Rosiglitazone) in premenopausal women with anovulation and insulin resistance (eg, patients with polycystic ovary syndrome) can lead to a resumption of ovulation. Such patients may become pregnant.
